Celestica Inc
CLS Information Technology · No analyses yet
What changed
No articles about this company yet. Follow it to hear when the first one appears.
Sector peers
How this company compares with 89 covered companies in Information Technology (median revenue change +20.6% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Celestica Inc CLS | — | — | — |
| Apple Inc. AAPL | $479B | +15.1% | 33.0% |
| Micron Technology Inc MU | $133B | +256.3% | 74.6% |
| NVIDIA Corp NVDA | $96.2B | +105.9% | 66.2% |
| Microsoft Corp MSFT | $92.3B | +18.8% | 49.8% |
| Accenture plc ACN | $74.2B | +6.5% | 15.4% |
| Dell Technologies Inc. DELL | $47B | +57.7% | 11.5% |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| Fidelity (FMR) | 8,446,912 | $3,081,285,654 | +11.7% | Q2 2026 |
| D. E. Shaw & Co. | 1,876,165 | $684,276,527 | +88.6% | Q2 2026 |
| Norges Bank (Norway's sovereign fund) | 1,494,469 | $544,786,949 | — | Q2 2026 |
| Geode Capital Management | 1,393,975 | $531,074,335 | +12.6% | Q2 2026 |
| Wellington Management | 807,509 | $294,572,744 | -29.0% | Q2 2026 |
| BlackRock | 613,620 | $223,848,723 | -50.6% | Q2 2026 |
| Citadel Advisors | 425,699 | $155,294,995 | +151.1% | Q2 2026 |
| Bridgewater Associates | 330,689 | $120,635,278 | -37.1% | Q2 2026 |
| Renaissance Technologies | 221,768 | $80,900,966 | -9.4% | Q2 2026 |
| Two Sigma Investments | 147,323 | $53,743,430 | -44.8% | Q2 2026 |
| Millennium Management | 135,536 | $49,422,820 | -5.2% | Q2 2026 |
| T. Rowe Price | 1,231,492 | $449,249 | -5.3% | Q2 2026 |
| Duquesne Family Office (Stanley Druckenmiller) | 33,275 | $9,373 | — | Q1 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.
